718 related articles for article (PubMed ID: 21881215)
1. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.
Jones SA; Scheller J; Rose-John S
J Clin Invest; 2011 Sep; 121(9):3375-83. PubMed ID: 21881215
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
3. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.
Tenhumberg S; Waetzig GH; Chalaris A; Rabe B; Seegert D; Scheller J; Rose-John S; Grötzinger J
J Biol Chem; 2008 Oct; 283(40):27200-7. PubMed ID: 18650419
[TBL] [Abstract][Full Text] [Related]
4. Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
Hashizume M; Mihara M
Rheumatol Int; 2009 Feb; 29(4):397-401. PubMed ID: 18802703
[TBL] [Abstract][Full Text] [Related]
5. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.
Rose-John S
Int J Biol Sci; 2012; 8(9):1237-47. PubMed ID: 23136552
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
7. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic implication of IL-6 blockade.
Tanaka T; Kishimoto T
Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
[TBL] [Abstract][Full Text] [Related]
9. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.
Rose-John S
Clin Pharmacol Ther; 2017 Oct; 102(4):591-598. PubMed ID: 28675418
[TBL] [Abstract][Full Text] [Related]
10. Targeting Interleukin-6 Signaling in Clinic.
Kang S; Tanaka T; Narazaki M; Kishimoto T
Immunity; 2019 Apr; 50(4):1007-1023. PubMed ID: 30995492
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
12. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
Cronstein BN
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S11-5. PubMed ID: 17708739
[TBL] [Abstract][Full Text] [Related]
14. The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
Rose-John S; Waetzig GH; Scheller J; Grötzinger J; Seegert D
Expert Opin Ther Targets; 2007 May; 11(5):613-24. PubMed ID: 17465721
[TBL] [Abstract][Full Text] [Related]
15. sIL-6R: more than an agonist?
Knüpfer H; Preiss R
Immunol Cell Biol; 2008 Jan; 86(1):87-91. PubMed ID: 17724457
[TBL] [Abstract][Full Text] [Related]
16. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
17. Role of interleukin-6, its receptor and soluble gp130 in chronic lung disease of prematurity.
Chakraborty M; McGreal EP; Davies PL; Nowell MA; Jones S; Kotecha S
Neonatology; 2013; 104(3):161-7. PubMed ID: 23921508
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J
J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364
[TBL] [Abstract][Full Text] [Related]
19. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer.
Jones SA; Jenkins BJ
Nat Rev Immunol; 2018 Dec; 18(12):773-789. PubMed ID: 30254251
[TBL] [Abstract][Full Text] [Related]
20. Development of a monoclonal antibody-based enzyme-linked immunoabsorbent assay for the binding of gp130 to the IL-6/IL-6R complex and its competitive inhibition.
Scheller J; Kovaleva M; Rabe B; Eichler J; Kallen KJ; Rose-John S
J Immunol Methods; 2004 Aug; 291(1-2):93-100. PubMed ID: 15345308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
